Mutanolysin
Based on 1 Customer Validation
Mutanolysin is a bacteriolytic agent. Mutanolysin is a muralytic enzyme that can prevent hepatic injury. Mutanolysin can digest the cell wall of S. mutans BHT and shows antibacterial activity. Mutanolysin reduces TNF-α production in isolated Kupffer cells stimulated with peptidoglycan-polysaccharide (PG-APS). Mutanolysin can be used for the researches of infection, inflammation and hepatic injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 55466-22-3
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Mutanolysin (200 μg; 36 h) digests PG-APS to reduce TNFα production by purified Lewis rat Kupffer cells by 75%, from 486 pg/mL to 145 pg/mL[1].
Mutanolysin (20 μg/mL, 90 min) lyses and kills live S. mutans AHT and BHT cells after 90 min of incubation, with 99.999% killing efficacy against S. mutans AHT and 99.0% killing efficacy against S. mutans BHT[2].
Mutanolysin exhibits broad lytic activity against gram-positive oral pathogens including S. mutans, A. viscosus, and L. acidophilus, but is inactive against S. aureus, gram-negative bacteria, and yeast[2].
Mutanolysin lyses S. mutans BHT cells by rupturing cell walls[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mutanolysin (0.4 mg; i.v.; single dose) completely prevents the development of chronic erosive arthritis, resolves acute arthritis within 14 days, and eliminates granulomatous lesions in visceral tissues[3].
Mutanolysin (0.4 mg; i.v.; single dose; administered 24 h or 3 days post-PG-APS) reduces acute arthritis severity and completely prevents the development of chronic erosive arthritis[3].
Mutanolysin (0.4 mg; i.v.; single dose; administered 14 days post-PG-APS) significantly reduces the severity of chronic joint disease, with only 33% of treated rats developing recurrent disease[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats (female, 100-120 g at time of PG-APS injection, arthritis model via intraperitoneal injection of arthropathic PG-APS)[3]
-
Dosage:0.4 mg
-
Administration:i.v.; single dose
-
Result:Prevented development of chronic erosive arthritis.
Resolved mild acute arthritis within 14 days.
Eliminated granulomatous lesions in liver, spleen, and mediastinal lymph nodes.
Reduced transient limb edema, which peaked at 2-3 hours and subsided by 9 hours.
Showed normal-appearing joint tissue with intact cartilage, no exudate, and only mild residual focal synovial scarring and lining cell hyperplasia at 41 days post-injection.
Demonstrated no chronic erosive arthritis on radiographic assessment.
Maintained tissue PG-APS levels in hind limbs, spleen, liver, and blood equal to or exceeding PBS-treated controls at days 2, 5, and 36 post-injection.
≥ 4000 U/mg protein
One unit is defined as the amount of enzyme that will produce a change in absorbance at 600 nm of 0.01 per minute at pH 6.0 at 37°C in a 1 mL volume using a suspension of Streptococcus faecalis cell wall as substrate
Chemical Information
-
CAS No. 55466-22-3
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Mutanolysin]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lichtman SN, et al. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest. 1992;90(4):1313-1322. [Content Brief]
[2]. Yokogawa K, et al. Mutanolysin, bacteriolytic agent for cariogenic Streptococci: partial purification and properties. Antimicrob Agents Chemother. 1974;6(2):156-165. [Content Brief]
[3]. Janusz MJ, et al. Treatment of experimental erosive arthritis in rats by injection of the muralytic enzyme mutanolysin. J Exp Med. 1984;160(5):1360-1374. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mutanolysin Related Classifications
HY-P3023 Related Classifications
Powered by Bioz